Compare MIND & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | NSRX |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | Israel |
| Employees | 157 | 7 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 38.9M |
| IPO Year | N/A | N/A |
| Metric | MIND | NSRX |
|---|---|---|
| Price | $4.97 | $3.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 79.5K | 11.0K |
| Earning Date | 04-15-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.31 | N/A |
| Revenue Next Year | $1.01 | N/A |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.66 | $1.98 |
| 52 Week High | $14.50 | $9.99 |
| Indicator | MIND | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.90 | 44.92 |
| Support Level | $4.83 | $2.83 |
| Resistance Level | $9.19 | $3.60 |
| Average True Range (ATR) | 0.35 | 0.16 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 17.05 | 28.87 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in single segment namely, Seamap which provides services and products, including engineering, repairs and software licensing, utilized in marine exploration, marine survey and maritime security for marine survey companies, seismic survey contractors, research institutes, non-military government organizations and operators of port facilities and other offshore installations. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.